Cargando…
P631: CHARACTERIZATION OF ZANUBRUTINIB SAFETY/TOLERABILITY PROFILE AND COMPARISON WITH IBRUTINIB PROFILE IN PATIENTS WITH B-CELL MALIGNANCIES: POST HOC ANALYSIS OF A LARGE CLINICAL TRIAL SAFETY DATABASE
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429013/ http://dx.doi.org/10.1097/01.HS9.0000969428.35688.4b |
| _version_ | 1785090609390813184 |
|---|---|
| author | Brown, Jennifer R. Eichhorst, Barbara Ghia, Paolo Jurczak, Wojciech Kahl, Brad Lamanna, Nicole Robak, Tadeusz Shadman, Mazyar Tam, Constantine Qiu, Lugui Cohen, Aileen Zhang, Meng Salmi, Tommi Paik, Jason Wang, Liping Zhang, Jun MA, Han Tedeschi, Alessandra |
| author_facet | Brown, Jennifer R. Eichhorst, Barbara Ghia, Paolo Jurczak, Wojciech Kahl, Brad Lamanna, Nicole Robak, Tadeusz Shadman, Mazyar Tam, Constantine Qiu, Lugui Cohen, Aileen Zhang, Meng Salmi, Tommi Paik, Jason Wang, Liping Zhang, Jun MA, Han Tedeschi, Alessandra |
| author_sort | Brown, Jennifer R. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429013 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104290132023-08-17 P631: CHARACTERIZATION OF ZANUBRUTINIB SAFETY/TOLERABILITY PROFILE AND COMPARISON WITH IBRUTINIB PROFILE IN PATIENTS WITH B-CELL MALIGNANCIES: POST HOC ANALYSIS OF A LARGE CLINICAL TRIAL SAFETY DATABASE Brown, Jennifer R. Eichhorst, Barbara Ghia, Paolo Jurczak, Wojciech Kahl, Brad Lamanna, Nicole Robak, Tadeusz Shadman, Mazyar Tam, Constantine Qiu, Lugui Cohen, Aileen Zhang, Meng Salmi, Tommi Paik, Jason Wang, Liping Zhang, Jun MA, Han Tedeschi, Alessandra Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429013/ http://dx.doi.org/10.1097/01.HS9.0000969428.35688.4b Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Brown, Jennifer R. Eichhorst, Barbara Ghia, Paolo Jurczak, Wojciech Kahl, Brad Lamanna, Nicole Robak, Tadeusz Shadman, Mazyar Tam, Constantine Qiu, Lugui Cohen, Aileen Zhang, Meng Salmi, Tommi Paik, Jason Wang, Liping Zhang, Jun MA, Han Tedeschi, Alessandra P631: CHARACTERIZATION OF ZANUBRUTINIB SAFETY/TOLERABILITY PROFILE AND COMPARISON WITH IBRUTINIB PROFILE IN PATIENTS WITH B-CELL MALIGNANCIES: POST HOC ANALYSIS OF A LARGE CLINICAL TRIAL SAFETY DATABASE |
| title | P631: CHARACTERIZATION OF ZANUBRUTINIB SAFETY/TOLERABILITY PROFILE AND COMPARISON WITH IBRUTINIB PROFILE IN PATIENTS WITH B-CELL MALIGNANCIES: POST HOC ANALYSIS OF A LARGE CLINICAL TRIAL SAFETY DATABASE |
| title_full | P631: CHARACTERIZATION OF ZANUBRUTINIB SAFETY/TOLERABILITY PROFILE AND COMPARISON WITH IBRUTINIB PROFILE IN PATIENTS WITH B-CELL MALIGNANCIES: POST HOC ANALYSIS OF A LARGE CLINICAL TRIAL SAFETY DATABASE |
| title_fullStr | P631: CHARACTERIZATION OF ZANUBRUTINIB SAFETY/TOLERABILITY PROFILE AND COMPARISON WITH IBRUTINIB PROFILE IN PATIENTS WITH B-CELL MALIGNANCIES: POST HOC ANALYSIS OF A LARGE CLINICAL TRIAL SAFETY DATABASE |
| title_full_unstemmed | P631: CHARACTERIZATION OF ZANUBRUTINIB SAFETY/TOLERABILITY PROFILE AND COMPARISON WITH IBRUTINIB PROFILE IN PATIENTS WITH B-CELL MALIGNANCIES: POST HOC ANALYSIS OF A LARGE CLINICAL TRIAL SAFETY DATABASE |
| title_short | P631: CHARACTERIZATION OF ZANUBRUTINIB SAFETY/TOLERABILITY PROFILE AND COMPARISON WITH IBRUTINIB PROFILE IN PATIENTS WITH B-CELL MALIGNANCIES: POST HOC ANALYSIS OF A LARGE CLINICAL TRIAL SAFETY DATABASE |
| title_sort | p631: characterization of zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in patients with b-cell malignancies: post hoc analysis of a large clinical trial safety database |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429013/ http://dx.doi.org/10.1097/01.HS9.0000969428.35688.4b |
| work_keys_str_mv | AT brownjenniferr p631characterizationofzanubrutinibsafetytolerabilityprofileandcomparisonwithibrutinibprofileinpatientswithbcellmalignanciesposthocanalysisofalargeclinicaltrialsafetydatabase AT eichhorstbarbara p631characterizationofzanubrutinibsafetytolerabilityprofileandcomparisonwithibrutinibprofileinpatientswithbcellmalignanciesposthocanalysisofalargeclinicaltrialsafetydatabase AT ghiapaolo p631characterizationofzanubrutinibsafetytolerabilityprofileandcomparisonwithibrutinibprofileinpatientswithbcellmalignanciesposthocanalysisofalargeclinicaltrialsafetydatabase AT jurczakwojciech p631characterizationofzanubrutinibsafetytolerabilityprofileandcomparisonwithibrutinibprofileinpatientswithbcellmalignanciesposthocanalysisofalargeclinicaltrialsafetydatabase AT kahlbrad p631characterizationofzanubrutinibsafetytolerabilityprofileandcomparisonwithibrutinibprofileinpatientswithbcellmalignanciesposthocanalysisofalargeclinicaltrialsafetydatabase AT lamannanicole p631characterizationofzanubrutinibsafetytolerabilityprofileandcomparisonwithibrutinibprofileinpatientswithbcellmalignanciesposthocanalysisofalargeclinicaltrialsafetydatabase AT robaktadeusz p631characterizationofzanubrutinibsafetytolerabilityprofileandcomparisonwithibrutinibprofileinpatientswithbcellmalignanciesposthocanalysisofalargeclinicaltrialsafetydatabase AT shadmanmazyar p631characterizationofzanubrutinibsafetytolerabilityprofileandcomparisonwithibrutinibprofileinpatientswithbcellmalignanciesposthocanalysisofalargeclinicaltrialsafetydatabase AT tamconstantine p631characterizationofzanubrutinibsafetytolerabilityprofileandcomparisonwithibrutinibprofileinpatientswithbcellmalignanciesposthocanalysisofalargeclinicaltrialsafetydatabase AT qiulugui p631characterizationofzanubrutinibsafetytolerabilityprofileandcomparisonwithibrutinibprofileinpatientswithbcellmalignanciesposthocanalysisofalargeclinicaltrialsafetydatabase AT cohenaileen p631characterizationofzanubrutinibsafetytolerabilityprofileandcomparisonwithibrutinibprofileinpatientswithbcellmalignanciesposthocanalysisofalargeclinicaltrialsafetydatabase AT zhangmeng p631characterizationofzanubrutinibsafetytolerabilityprofileandcomparisonwithibrutinibprofileinpatientswithbcellmalignanciesposthocanalysisofalargeclinicaltrialsafetydatabase AT salmitommi p631characterizationofzanubrutinibsafetytolerabilityprofileandcomparisonwithibrutinibprofileinpatientswithbcellmalignanciesposthocanalysisofalargeclinicaltrialsafetydatabase AT paikjason p631characterizationofzanubrutinibsafetytolerabilityprofileandcomparisonwithibrutinibprofileinpatientswithbcellmalignanciesposthocanalysisofalargeclinicaltrialsafetydatabase AT wangliping p631characterizationofzanubrutinibsafetytolerabilityprofileandcomparisonwithibrutinibprofileinpatientswithbcellmalignanciesposthocanalysisofalargeclinicaltrialsafetydatabase AT zhangjun p631characterizationofzanubrutinibsafetytolerabilityprofileandcomparisonwithibrutinibprofileinpatientswithbcellmalignanciesposthocanalysisofalargeclinicaltrialsafetydatabase AT mahan p631characterizationofzanubrutinibsafetytolerabilityprofileandcomparisonwithibrutinibprofileinpatientswithbcellmalignanciesposthocanalysisofalargeclinicaltrialsafetydatabase AT tedeschialessandra p631characterizationofzanubrutinibsafetytolerabilityprofileandcomparisonwithibrutinibprofileinpatientswithbcellmalignanciesposthocanalysisofalargeclinicaltrialsafetydatabase |